Table 1.
Demographic and clinical characteristics of PD patients and healthy control subjects.
| Demographic and clinical variables | PD patients, Mean ± SD (range) | Healthy controls, Mean ± SD (range) |
|---|---|---|
| Age, years | 64.9 ± 7.9 (46–82) | 63.3 ± 8 (46–83) |
| Gender (male/female) | 15/12 | 15/14 |
| Education, years | 13.5 ± 2.7 (8–18) | 14.7 ± 3.5 (11–25) |
| Disease duration, years | 11.1 ± 3.7 (4–18) | — |
| H/Y stage ON medication | 2 ± 0.5 (1–3) | — |
| UPDRS-III ON medication | 14.4 ± 7.1 (4–31) | — |
| LEDD | 1306.1 ± 616.7 (450–2371) | — |
| BDI-II | 10 ± 4.8 (2–21) | 6.9 ± 5.2 (0–19) |
| STAI-X1 (state) | 38.7 ± 9.4 (28–64) | 32.7 ± 5.7 (20–47) |
| STAI-X2 (trait) | 41.8 ± 8.9 (27–56) | 35.1 ± 8.2 (22–55) |
| Starkstein apathy scale | 10 ± 4.7 (0–19) | 9.58 ± 4.4 (1–21) |
| MoCA | 26 ± 2.2 (20–29) | 26.6 ± 2.2 (22–30) |
| PD-MCI score | 2 ± 2.1 (0–7) | 0.14 ± 0.3 (0–1) |
Abbreviations: H/Y, Hoehn and Yahr; LEDD, Levodopa equivalent daily dose65; BDI-II, Beck Depression Inventory, second edition; STAI, Spielberger State-Trait Anxiety Inventory; MoCA, Montreal Cognitive Assessment.